In the past two months, PD-1/PD-L1 antibodies have achieved many good news in succession. The first PD-L1 antibody Tecentriq for the treatment of metastatic non-small cell lung cancer (NSCLC) was approved, the PD-1 antibody Keytruda was officially approved for first-line treatment of NSCLC, the PD-1 antibody Opdivo took the head and neck cancer indication, and advanced gastric cancer Phase III clinical success, these messages once again demonstrate the subversive anticancer effect of immunological checkpoint inhibitors. Excellent "player": PD-1/PD-L1 antibody family At present, the immune checkpoint inhibitor antibody family has taken various types of indications such as melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and classic Hodgkin's lymphoma. So, what are the rewards of these drugs for their companies? According to statistics, in 2015, BMS's Opdivo had annual sales of $942 million, and Merck's Keytruda had sales of $566 million. So far, the benefits of the two PD-1 antibodies for the two companies in 2016 have far exceeded 2015. Opdivo's sales in the first three quarters of this year reached 2.464 billion US dollars (Q1: 704 million US dollars; Q2: 840 million US dollars; Q3: 920 million US dollars), Keytruda cumulative sales for the same period of 919 million US dollars (Q1: 249 million US dollars; Q2: $314 million; Q3: $3.56). Roche Tecentriq (approved for the first indication in May this year) had sales of CHF 77 million in the same period. The entire market: in 2021, the scale will reach 119.39 billion US dollars US market research firm MarketsAndMarkets released the global cancer immunotherapy market analysis report released in September, indicating that in 2021, the market size will increase from $61.9 billion in 2016 to $119.39 billion, with a compound annual growth rate of 14.0%. According to the report, the global cancer immunotherapy market can be divided into monoclonal antibodies, cancer vaccines, checkpoint inhibitors and immunomodulators based on type. Among them, the monoclonal antibody part is expected to occupy the largest share of the cancer immunotherapy market in 2016. Based on indications, the entire market can be divided into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others. In the next five years, the compound annual growth rate of the lung cancer market is expected to be the highest. Such a huge market has triggered a fierce battle for international giants. "Big players" in the field of cancer immunotherapy include Amgen (USA), AstraZeneca (UK), Roche (Switzerland), Bayer (Germany), BMS (USA), Lilly (USA), Janssen (Belgium), Merck (USA), Novartis (Switzerland) and Pfizer (USA). Erythritol For Food,Erythrit Erythritol,Maltitol Erythritol,Erythritol Mercadona Ningxia Eppen Biotec CO.,LTD , https://www.nxeppen.com![[Heavy] The market for immunotherapy will reach 120 billion by 2021.](http://i.bosscdn.com/blog/12%20(1).jpg)
![[Heavy] The market for immunotherapy will reach 120 billion by 2021.](http://i.bosscdn.com/blog/12%20(2).jpg)